BackAcorda Therapeutics Overview

Acorda Therapeutics Long Term Debt

Track Acorda Therapeutics's long-term debt ($2.8M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$2.85M
↓ 98.38% YoYΔ $-172.70M vs prior year quarter

Peer average

Loading

Acorda Therapeutics Long Term Debt History

Loading

Acorda Therapeutics vs. peers: Long Term Debt Comparison

Loading

Acorda Therapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Acorda Therapeutics (ACOR) FAQ

As of the most recent data (March 2024), ACOR shows a long-term debt of $2.8M. That compares with $180M in the prior-year period — down 98.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ACOR's long-term debt is now $2.8M (was $180M) — a 98.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Acorda Therapeutics is outperforming or lagging.

Tracking ACOR's long-term debt over time shows whether Acorda Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $2.8M That compares with $180M in the prior-year period — down 98.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Acorda Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $2.8M) with ownership activity and broader fundamentals.

Acorda Therapeutics's long-term debt is $2.8M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.